Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback